The Government is following expert, independent advice from the Cass Review to implement a programme of research to support high quality National Health Service care for children and young people with gender incongruence. Responding to the specific recommendations of the review, the programme includes the PATHWAYS trial, a carefully designed clinical trial to assess the relative benefits and harms of puberty-suppressing hormones as a treatment option for children and young people with gender incongruence when provided alongside an updated model of NHS care incorporating holistic assessment and a tailored package of psychosocial support.

The trial is now in the set-up phase following comprehensive independent scientific, ethical, and regulatory review and approvals. It was designed by an independent research team, in conjunction with patient and public involvement as well as independent ethics, clinical, and legal experts. The team responsible for the protocol design have given considerable thought to the most appropriate eligibility criteria for entry into the trial, and to the physical and mental outcome measures to be monitored, to properly assess and protect young people's wellbeing.